Insider Trading June 29, 2026 08:04 PM

Glenbrook Capital Management Expands SenesTech Position Amid Market Contraction

Insider accumulation at $39,102 signals potential inflection point for the rodenticide manufacturer as it navigates regulatory shifts and operational expansion.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SNES

Glenbrook Capital Management, acting as investment manager for a ten percent shareholder account in SenesTech Inc. (NASDAQ: SNES), executed a series of open market purchases totaling $39,102 across four trading days in late June 2026. The acquisition of 25,416 shares occurred at prices between $1.5244 and $1.5558, positioning the fund near the stock's 52-week low of $1.41. This strategic accumulation coincides with SenesTech's recent operational milestones, including a record gross margin in the first quarter of 2026 and strategic leadership appointments aimed at bolstering revenue growth. The company also announced a distribution partnership in Bermuda and adjusted its equity incentive plan, reflecting a broader effort to optimize financial strategies and expand market reach in the pest control sector.

Glenbrook Capital Management Expands SenesTech Position Amid Market Contraction
SNES
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Glenbrook Capital Management acquired 25,416 shares of SenesTech for $39,102 in late June 2026, increasing its indirect stake to 987,824 shares.
  • SenesTech reported a record gross margin of 68.6% in Q1 2026 and appointed Jack Karabees as EVP of Sales to drive market expansion.
  • The company announced a distribution agreement in Bermuda and adjusted its equity incentive plan, signaling strategic growth and financial optimization.

Glenbrook Capital Management has significantly increased its exposure to SenesTech Inc. (NASDAQ: SNES) through a calculated series of open market purchases. Acting as the investment manager for an account holding a ten percent stake in the company, the fund acquired 25,416 shares of SenesTech common stock over a concentrated four-day period in late June 2026. The total value of these transactions reached $39,102, with shares purchased at prices ranging from $1.5244 to $1.5558 per unit.

This accumulation occurred while the stock was trading near its 52-week low of $1.41, a level that reflects a substantial 71% decline over the past year. According to InvestingPro analysis, the current valuation suggests the stock may be undervalued, indicating potential upside for investors monitoring the pest control and agricultural inputs sector. The transactions were executed on June 24, 2026, with 3,990 shares acquired; followed by 9,442 shares on June 25; 6,812 shares on June 26; and concluding with 5,172 shares on June 29.

Following these purchases, Glenbrook Capital Management holds a total of 987,824 shares of SenesTech's common stock indirectly. The reporting entity disclaims beneficial ownership except to the extent of its pecuniary interest. This activity highlights the fund's continued confidence in SenesTech's long-term prospects despite recent market headwinds.

SenesTech's operational performance has shown recent improvements that may underpin this institutional interest. The company reported a modest 2% increase in revenue for the first quarter of 2026, reaching $493,000 compared to $485,000 in the same period last year. More notably, SenesTech achieved a record gross margin of 68.6%, an improvement from 64.5% in the first quarter of 2025. To support further growth, the company appointed Jack Karabees as Executive Vice President of Sales. Karabees brings over 30 years of experience in B2B sales organizations and is expected to bolster revenue growth, market expansion, and customer relationships.

Strategic expansion efforts also include a new distribution agreement with Animal and Garden House to introduce Evolve Rodent Birth Control products to the Bermuda market. This entry is significant as traditional rodenticides face regulatory restrictions in Bermuda due to environmental concerns, positioning SenesTech's biological solutions as a viable alternative. Additionally, the Board of Directors amended a proposal to increase shares available under its 2018 Equity Incentive Plan, reducing the requested amount from 1.7 million shares to 1.2 million shares. This amended proposal will be presented to stockholders for approval in June 2026, reflecting ongoing efforts to optimize financial strategies and align equity compensation with shareholder interests.

Risks

  • The stock has declined 71% over the past year and is trading near its 52-week low of $1.41, indicating significant market pressure.
  • SenesTech's revenue growth remains modest at 2% year-over-year, suggesting potential challenges in scaling operations.
  • The reduced equity incentive plan proposal requires stockholder approval, introducing uncertainty regarding executive compensation alignment.

More from Insider Trading

CrowdStrike CEO George Kurtz Executes $1.19M Stock Sale Under Pre-Arranged Plan Jun 29, 2026 Schorsch Affiliates Acquire NYC Shares Amidst Revenue Decline and Valuation Concerns Jun 29, 2026 CrowdStrike CEO George Kurtz Executes $2.2M Share Sale Under Pre-Arranged Plan Jun 29, 2026 NextNav Executive Shams Sammaad Executes Pre-Arranged Stock Sale Under Rule 10b5-1 Plan Jun 29, 2026 Tempus AI CFO James Rogers Executes $634,095 Stock Sale Under Pre-Arranged Plan Jun 29, 2026